Similarly, BCL2 inhibitors like venetoclax are highly effective in TP53-mutated CLL, but resistance can emerge due to mutations in BCL2 itself, leading to therapeutic failure [201]. The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.